GB1036621A - Improvements in or relating to bacterial vaccines - Google Patents
Improvements in or relating to bacterial vaccinesInfo
- Publication number
- GB1036621A GB1036621A GB6820/63A GB682063A GB1036621A GB 1036621 A GB1036621 A GB 1036621A GB 6820/63 A GB6820/63 A GB 6820/63A GB 682063 A GB682063 A GB 682063A GB 1036621 A GB1036621 A GB 1036621A
- Authority
- GB
- United Kingdom
- Prior art keywords
- vaccines
- dornase
- staphylococci
- infections
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960001212 bacterial vaccine Drugs 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 5
- 241000295644 Staphylococcaceae Species 0.000 abstract 3
- 208000004396 mastitis Diseases 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 208000034762 Meningococcal Infections Diseases 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 201000005702 Pertussis Diseases 0.000 abstract 1
- 206010041925 Staphylococcal infections Diseases 0.000 abstract 1
- 206010061372 Streptococcal infection Diseases 0.000 abstract 1
- 102000004142 Trypsin Human genes 0.000 abstract 1
- 108090000631 Trypsin Proteins 0.000 abstract 1
- 208000037386 Typhoid Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 230000002934 lysing effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000000392 somatic effect Effects 0.000 abstract 1
- 239000012588 trypsin Substances 0.000 abstract 1
- 201000008297 typhoid fever Diseases 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Somatic antigen vaccines are prepared by lysing the killed cells of at least one selected strain of pathogenic bacteria other than staphylococci by exposing them to the action of dornase. It is preferred to inactivate the dornase but this must be done without destroying the antigenic properties of the vaccine e.g. by heating at 56 DEG C for 1 hour. Vaccines derived from staphylococci may be obtained in this preferred way, especially vaccines for treating mastitis in cattle and derived from mixed strains of both staphylococci and streptococci. A proteolytic enzyme such as trypsin may be added to the dornase and lysis may be expedited by the further addition of a wetting agent. Examples relate to the preparation of vaccines effective against staphylococcal infections, typhoid, meningococcal infections, pertussis, streptococcal infections, BCG and mastitis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA843020 | 1962-02-23 | ||
| CA851099 | 1962-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1036621A true GB1036621A (en) | 1966-07-20 |
Family
ID=25673389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB6820/63A Expired GB1036621A (en) | 1962-02-23 | 1963-02-20 | Improvements in or relating to bacterial vaccines |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR2774M (en) |
| GB (1) | GB1036621A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2510987A1 (en) * | 1974-10-29 | 1976-05-13 | Behringwerke Ag | Atoxic, immunogenic prod. from tetanus toxin - by treatment with proteinase, giving vaccines which cause fewer reactions on inoculation |
| EP0174106A3 (en) * | 1984-08-23 | 1986-03-26 | Becton, Dickinson And Company | Detection of cell membrane protein |
| US5576003A (en) * | 1992-10-14 | 1996-11-19 | Akzo Nobel N.V. | Ornithobacterium rhinotracheale vaccine and method of immunization |
-
1963
- 1963-02-20 GB GB6820/63A patent/GB1036621A/en not_active Expired
- 1963-02-22 FR FR925793A patent/FR2774M/en not_active Expired
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2510987A1 (en) * | 1974-10-29 | 1976-05-13 | Behringwerke Ag | Atoxic, immunogenic prod. from tetanus toxin - by treatment with proteinase, giving vaccines which cause fewer reactions on inoculation |
| EP0174106A3 (en) * | 1984-08-23 | 1986-03-26 | Becton, Dickinson And Company | Detection of cell membrane protein |
| AU582170B2 (en) * | 1984-08-23 | 1989-03-16 | Becton Dickinson & Company | Detection of cell membrane protein |
| US5576003A (en) * | 1992-10-14 | 1996-11-19 | Akzo Nobel N.V. | Ornithobacterium rhinotracheale vaccine and method of immunization |
| US5925361A (en) * | 1992-10-14 | 1999-07-20 | Akzo Nobel, N.V. | Ornithobacterium rhinotracheale vaccines |
| US6114131A (en) * | 1992-10-14 | 2000-09-05 | Akzo Nobel N.V. | Methods for the detection of antibodies to ornithobacterium rhinotracheale |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2774M (en) | 1964-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT88329A (en) | NON-VIRULENT BACTERIA AGAINST STREPTOCOCCAL INFECTIONS | |
| CA2022420A1 (en) | Escherichia coli vaccine | |
| SE324208B (en) | ||
| US3532790A (en) | Somatic antigen vaccines from lysed inactivated bacteria and process for producing them | |
| GB1256456A (en) | Ethylethyleneimine as inactivating agent in antigen-containing pharmaceutical preparations | |
| ES477212A1 (en) | E. Coli enterotoxin vaccine for veterinary & human use and process for its preparation. | |
| GB1036621A (en) | Improvements in or relating to bacterial vaccines | |
| ES426215A1 (en) | Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them | |
| Weiss | Observations on Bacterium melaninogenicum: Demonstration of Fibrinolysin, Pathogenicity and Serological Types. | |
| IE38423B1 (en) | Vaccine for nenatal calf diarrhea | |
| Schütze | Studies in B. pestis antigens: Iii. The prophylactic value of the envelope and somatic antigens of B. pestis | |
| ATE201448T1 (en) | VACCINES BASED ON STREPTOKINASE | |
| Ljunggren | Transfer of virulence in Rhizobium trifolii | |
| Muir et al. | ON THE BACTERICIDAL ACTION OF NORMAL SERUM. ¹ 2 | |
| Wheeler | Notes on the antigenic activity of hemolytic streptococci from different types of infection | |
| US3288680A (en) | Stabilized clostridium perfringens beta-toxoid vaccine | |
| Corbel et al. | The relationship of Brucella abortus agglutinogenic antigens to the receptor sites for Tbilisi phage | |
| Davis et al. | Complement deviation in Rocky Mountain spotted fever | |
| GB1002062A (en) | Process for the toxoidification of bacterial toxins | |
| GB1234747A (en) | Improvements in or relating to the protection of domestic animals against pathogenic organisms | |
| GB1100190A (en) | Somatic antigen vaccines | |
| ATE318300T1 (en) | ISOLATED STRAINS OF STAPHYLOCOCCUS AUREUS AND VACCINES PRODUCED THEREFROM | |
| GB970365A (en) | Preparations for the treatment of tumours | |
| GB1351343A (en) | Methods of preparation and use of a vaccine from bacteroides nodosus | |
| Claus et al. | Immunogenicity of Clostridium septicum in guinea pigs |